EYEN Eyenovia
- 0.694
- -0.017-2.40%
Eyenovia News
All You Need to Know About Eyenovia (EYEN) Rating Upgrade to Buy
Earnings Call Summary | Eyenovia(EYEN.US) Q1 2024 Earnings Conference
The following is a summary of the Eyenovia, Inc. (EYEN) Q1 2024 Earnings Call Transcript:Financial Performance:Eyenovia reported a Q1 2024 net loss of about $10.9 million or $0.23 per share. This incl
Why Fluent Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Fluent Inc (NASDAQ:FLNT) fell sharply during Thursday's session after posting weaker-than-expected quarterly results.Fluent posted adjusted loss of 30 cents per share, versus market expectat
SYTA, DATS and CYN Among Mid-day Movers
Analysts Offer Insights on Healthcare Companies: Eyenovia (EYEN), Alpine Immune Sciences (ALPN) and GoodRx Holdings (GDRX)
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersLucy Scientific Discovery (NASDAQ:LSDI) stock moved upwards by 123.5% to $1.14 during Thursday's pre-market session. The market value of their outstanding shares is at $2.0 million. SINTX Techs
HC Wainwright & Co. Reiterates Buy on Eyenovia, Maintains $12 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Eyenovia (NASDAQ:EYEN) with a Buy and maintains $12 price target.
Eyenovia Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 1248.31% HC Wainwright & Co. → $12 Reiterates Buy → Buy 03/19/2024 1248.31% HC Wainwright & Co.
Eyenovia Inc (EYEN) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges and ...
Express News | Eyenovia Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results
Eyenovia | 10-Q: Quarterly report
Express News | Eyenovia Q1 2024 GAAP EPS $(0.23) Misses $(0.17) Estimate, Sales $4.993K Miss $816.667K Estimate
Eyenovia Prepares for 3Q Launch of Ophthalmic Steroid to Treat Inflammation and Pain Following Ocular Surgery >EYEN
Eyenovia Prepares for 3Q Launch of Ophthalmic Steroid to Treat Inflammation and Pain Following Ocular Surgery >EYEN
Eyenovia Remains on Track Toward Accelerating Devt of MicroPine >EYEN
Eyenovia Remains on Track Toward Accelerating Devt of MicroPine >EYEN
Express News | Eyenovia Inc - Requested Meeting With FDA to Discuss Validation of the Gen-2 Dispenser, Which We Anticipate Will Occur This Summer
Express News | Eyenovia, Inc. Q1 Net Income USD -10.9 Million
Express News | Eyenovia, Inc. Q1 Operating Expenses USD 10.3 Million
Press Release: Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on Its Myopia Phase III Program and Its Two FDA Approved Commercial Products, Mydcombi and Clobetasol
Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol.
Eyenovia 1Q Loss/Shr 23c >EYEN
Eyenovia 1Q Loss/Shr 23c >EYEN
Express News | Eyenovia, Inc. Q1 Basic EPS USD -0.23
Analysis
Price Target
No Data
